SCHEMBL205341

SCHEMBL205341

CCCCCOc1ccc(Nc2nc(-c3cccnc3)cs2)cn1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.64
MEN1 O00255 11/20 0.64
KMT2A Q03164 11/20 0.64
NPC1 O15118 10/20 0.64
MAPK1 P28482 3/20 0.61
MAPT P10636 7/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
GAA P10253 4/20 0.59
CASP3 P42574 2/20 0.59
SENP8 Q96LD8 2/20 0.59
SENP7 Q9BQF6 2/20 0.59
SENP6 Q9GZR1 2/20 0.59
LMNA P02545 2/20 0.56
PKM P14618 1/20 0.56
VCP P55072 1/20 0.56
TP53 P04637 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
NCOA3 Q9Y6Q9 1/20 0.53
ALDH1A1 P00352 2/20 0.52
CLK1 P49759 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206322 0.99 MEN1 (0.63) RAB9AMEN1KMT2ANPC1MAPK1
SCHEMBL204346 0.88 MEN1 (0.80) RAB9AMEN1KMT2ANPC1MAPK1
SCHEMBL205584 0.87 MEN1 (0.78) RAB9AMEN1KMT2ANPC1MAPK1
SCHEMBL205058 0.87 MEN1 (0.78) RAB9AMEN1KMT2ANPC1MAPK1
SCHEMBL205300 0.87 MEN1 (0.78) RAB9AMEN1KMT2ANPC1MAPK1
SCHEMBL206783 0.86 MEN1 (0.46) RAB9AMEN1KMT2ANPC1MAPK1
SCHEMBL205405 0.85 MEN1 (0.67) RAB9AMEN1KMT2ANPC1MAPK1
SCHEMBL3131988 0.85 MEN1 (0.67) RAB9AMEN1KMT2ANPC1MAPK1
SCHEMBL206385 0.85 MEN1 (0.83) RAB9AMEN1KMT2ANPC1MAPK1
SCHEMBL3124616 0.84 MEN1 (0.66) RAB9AMEN1KMT2ANPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US claimed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 RAB9A 1357/4885MEN1 3862/4885KMT2A 3476/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 RAB9A 1357/4885MEN1 3862/4885KMT2A 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.